ProfileGDS5678 / 1459402_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 36% 35% 35% 34% 35% 33% 35% 34% 34% 35% 51% 32% 33% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.859136
GSM967853U87-EV human glioblastoma xenograft - Control 22.7887235
GSM967854U87-EV human glioblastoma xenograft - Control 32.7921735
GSM967855U87-EV human glioblastoma xenograft - Control 42.718534
GSM967856U87-EV human glioblastoma xenograft - Control 52.7381935
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8384533
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8441535
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7655834
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7448334
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.772235
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2185451
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6942732
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7507633
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7763134